
Azadpur Commercial Complex, Delhi - 110 033

Telefax: +91 1127679700-05 (6 Lines) e mail : info@insecticidesindia.com

Regd. & Corporate Office: 401-402, Lusa Tower







ISO 9001, 14001 & OHSAS 18001 ISO 9001 ISO 14001 CERTIFIED COMPANY

> Ref: IIL/SE/2021/0510/01 October 05, 2021

The Manager

Listing Compliance Department	Listing Compliance Department
BSE Limited	National Stock Exchange of India Limited
(Through BSE Listing Centre)	(Through NEAPS)
Scrip Code: 532851	Symbol: INSECTICID

Dear Sir/Madam,

Sub: Investor Presentation

Please find enclosed the Investor Presentation

The same will also be available on the website of the Company at https://www.insecticidesindia.com/investors-desk/

This is for information and records.

Thanking You,

For Insecticides (India) Limited

Sandeep Kumar

Company Secretary & Chief Compliance Officer





Safe Harbour

Certain statements in this document may be forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Insecticides (India) Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.







IIL's Dashboard

BACKGROUND

One of India's Leading Agrochemicals Manufacturers

1,250+ Employees

Owner of prestigious Tractor Brand



5,000+ 3

375+

DISTRIBUTORS

SKUS

10,00,000+

FARMERS IN TOUCH

60,000+
DEALERS



PRODUCTS

22 TECHNICAL PRODUCTS

FORMULATION 1 0 +

20 MAHARATNA PRODUCTS



TECHNICAL FACILITIES

SYNTHESIS PLANTS

FORMULATION 6
PLANTS

TOLL
MANUFACTURING
BIOLOGICAL
PLANT
CENTRES



Our journey so far

2003

Acquired 21

Brands of

Industries

Montari

2002

Plant

Chopanki

(Rajasthan)

Formulations

Commenced

Production

2007

2005

Chopanki

Plant Got

ISO 9001:2008

Certification;

2004

Sambha

(J&K) Plant

Commissioned

Set Up R&D

Lab

Listed on NSE and BSE; Chopanki Technical Plant Commenced: SambaPlant Expansion

2006

Two Plants (Dahei and Udhampur)

Commissioned

2011

Acquired

MONOCIL

from NOCIL:

2008 Received OHSAS18001 Certification

Technical Collaboration with AMVAC, USA to manufacture and market Thimet Tie-Up with

2014

Product

Invention

in JV with

(Japan);

New

unit in

R&D Centre

OAT AgiroCo.

Commenced

Formulations

Chopanki

2012

Launched

AMVAC:

launched

HAKAMA and

NISSAN(Japan)

PULSOR With

NUVAN With

Commenced

2016

MOMENTIVE (USA) For AGRO SPRED* MAX; Tie-Up with NIHON NOHYAKU(Japan) for SUZUKA and HAKKO; Launched GREEN LABEL (Bispyribac Sodium 10% SC); Manufactured in India for the First time

2015

Launched **Bio-Product** MYCORAYA; **Bonus Shares** Issued; Followed By **OIPs**

2020

Started with Export Oriented Unit (EOU) at SEZ, Dahej, Gujarat and launched 7 new products.

2021

Launched new patented product Hachiman



2018

2019

and

Launched

KUNOICHI

CHAPERONE

Product Launched Under 9(3) Registration (Sofia, Encounter, Hercules and Aikido)

2001

Commenced Operation





Update on Capex

Company had guided last year about its expansion plans at 5 locations, (including 3 major and 2 minor expansions) in a span of 2 years (FY21 and FY22).

These expansions combined required a total of ₹ 1,100 mn, out of which ₹ 420 mn has already been deployed by the company in last year.





The expansions were aimed to increase capabilities at both technical and formulation units in Chopanki (Rajasthan) and Dahej (Gujarat). The major expansion was in Dahej (SEZ) technical synthesis plant which was completed in Q1FY22 and production has commenced since June, 2021.



Out of the balance ₹ 680 mn to be utilized in FY22, the company has already utilized ₹ 100 mn in Q1 FY22.





Aggregate Installed Capacity

30,900_{KLPA} Liquid

80,750_{MTPA}

Granules


24,770_{MTPA} **Powder**

13,800_{MTPA} Active Ingredient and Bulk.

Formulation

Chopanki, Rajasthan

Unit II:





Products Launched in FY21

Dominant Tadaaki Mahir Avval Master Stroke Hakama Super

BIOLOGICAL

Milstim Max


Aggregate Revenue in FY21 from these New Launches:

₹ 321.58mn










- Maharatna Products
- Other Products



- Maharatna Products
- Other Products


IIL Heading Towards Premiumization





Product Freshness Index

IIL's consistent success in adding new products every year led by its strong In-House R&D Capabilities and its endeavours to deliver effective and cost-efficient products every year.



FY	2013	2014	2015	2016	2017	2018	2019	2020	2021	Q1 FY22
New Products Launched During the year	5	5	3	2	5	5	8	8	7	-
% of Revenue from Operations	7.1%	19.9%	22.9%	30.3%	37.9%	43.1%	44.8%	41.9%	35.7%	34%







- **Product Discovery in JV with** OAT Agrio Co. Ltd. (Chopanki, Rajasthan)
- **Reverse Engineering Products** (Chopanki, Rajasthan)
- **Biological Products** (Shamli, UP)
- **Combination & Formulations Products** (Dahej Gujarat)
- **Market Development**









In-house R&D Centres

State-of-the-art R&D centre

IIL's in-house R&D centre was established in 2005, augmented by product innovation R&D centre, formulation R&D centre and biological R&D centre

- Approved by DSIR, Ministry of Science and Technology
- Working on new formulations and new combination products
- Synthesis of new molecules in process

Formulation R&D Centre


- Development of new generation formulations
- Focus on cost reduction, customer friendly and environment safe products

Biological R&D Centre

- Equipped with bio assay and product development facilities
- Looking forward to development of 3-4 new biological products

Product invention R&D centre: A unique initiative of product discovery in India by forming a JV a with Japanese company, OAT Agrio Co. Ltd.

- Two different sections of Chemical & Biological Laboratories
- Equipped with the latest machines and equipment's like NMR, Lab set designed by Kewanee, USA
- Lead by the internationally renowned scientists with more than 25 years of experience
- Ultra-modern green houses to compliment effective testing
- One of its kind breeding centres, bio assay rooms and spray cabinets





Our Differentiating Business Structure



SALES AND MARKETING

Sales & Market development Branding International Tie ups and Collaborations



MANUFACTURING

6 Formulation Plants2 Technical Synthesis Plants1 Toll Manufacturing Biological Plant



RESEARCH & DEVELOPMENT

NABL QC Labs
4 R&D Centres
Each R&D centre focussed
on specific developments
JV with OAT Agrio Co. Japan
for dedicated invention R&D centre



DEVELOPMENT & TRAINING

Emphasis on field activities
Farmer Awareness
Sales force Training
Digital initiatives- Provided training
to Sales Team for Customer
engagements through Digital
Media



Biological Products - Game Changer

BIOLOGICAL R&D CENTRE

Equipped with bio assay and product development facilities such as Isolation, detection and multiplication of biological microorganisms.

Made a break through by developing and commercializing VAM (Vaslcular Arbuscular Mycorrhiaze).

Looking forward to development of 3-4 new biological products.

BIOLOGICAL FACILITIES

Sterile environment; Latest ultra-modern production facilites; Automatic filling lines.

Products manufactured are organic certified.

Biological products are manufactured under the expert supervision of bio technologists and Micro biologists.

The QC facility are equipped with latest instruments for detection and quantification of microorganisms.

BIOLOGICAL SOLUTION

Competitive Advantage due to lesser no. of players.

One-stop solution for farmers for availing both agrochem as well as biological inputs to enhance yield.

Developed & commercialized Vascular Arbuscular Mycorrhizae.

KK Pro - Improvised version of Kayakalp, widely accepted by farmer community.


FEW CREDIBLE BIOLOGICAL PRODUCTS

KK Pro has been created to replenish the soil, increase its organic carbon and improve its physical properties.

Mycoraja equipped to promote healthy growth and greater nutrient absorption in a wide range of crops, oilseeds and cotton.

Surya Zinc+ is an effective biological carrier-based formulation of Zinc solubilising bacteria in the form of a dry powder that solubilizes soil zinc and makes it available to plants.

AgroSpred Max, a silicone based super spreader, helps increase the bio efficacy of crop protection chemicals, growth promoters and micronutrients.







Insecticides

Bheema, Dominant, Encounter, Hercules, Kunoichi, Lethal Gold, Lethal 10G, Lethal Super 505, Victor Gold, Xplode

Herbicides

Flite 71, Green Label, Green Mix, Hakama, Hijack Super

Fungicides

Pulsor, Sofia

PGRs/Biologicals

Mycoraja, AgroSpred Max, Prime Gold

Maharatna Brands





Substitutes for Nuvan and Thimet



Thimet
Revenue in FY20
₹770 mn

SUBSTITUTE

SUBSTITUTE

Lethal Gold

Revenue in FY21 ₹ 120.10 mn

Lethal Granules & Tadaaki

Aggregate Revenue in FY21 ₹ 564.97 mn





Business Strength



STRONG INTEGRATION
AMONG EMPLOYEES
AND CHANNEL
PARTNERS



STRONG MARKETING TEAM; WIDE AND DEEP DISTRIBUTION NETWORK



STATE-OF-THE-ART
MANUFACTURING FACILITIES;
ONE OF THE LARGEST
FORMULATIONS FACILITY



BACKWARD INTEGRATION; PROCESS EFFICIENCY



STRONG COLLABORATIONS WITH INTERNATIONAL PLAYERS



IN-HOUSE R&D TEAM;
DEVELOPMENT OF
INNOVATIVE AND
VALUE-ADDED PRODUCTS



COMPANY WITH
INDIGENOUS
TECHNICAL LICENSE
TO MANUFACTURE
TECHNICAL



WIDENING INTERNATIONAL FOOTPRINT





STRONG CREDIT-RATING



Knowledge Pool



44

Ensuring farmers' holistic welfare is the foundation of our alliance with the them."

Mr. H. C. Aggarwal Chairman

Management Team consists of senior and experienced players of the industry

46

Inherent resilience and the unparalleled dedication of our team will help us navigate through the exciting times ahead and continue to create unmatched value for all."

Mr. Rajesh Aggarwal Managing Director



Board of Directors and Management

BOARD OF DIRECTORS

- Mr. H.C. Aggarwal, Chairman
- Mr. Rajesh Aggarwal, Managing Director
- Mrs. Nikunj Aggarwal, Whole Time Director
- Mr. Virjesh Kumar Gupta, Independent Director
- Mr. Navin Shah, Independent Director
- Mr. Jayaraman Swaminathan, Independent Director
- Mrs. Praveen Gupta, Independent Director

KEY MANAGEMENT



H.C. Aggarwal Chairman



Rajesh Aggarwal Managing Director



Sandeep Aggarwal



Sandeep Kumar CCO & Company Secretary



P C Pabbi Sr. Vice President



V K Garg Vice President



M K Singhal Vice President



Sanjay Vats Vice President



Shrikant Satwe Head – International Business



Dr. Arun Kohli Vice President – Institutional Sales



Sanjeev Aggarwal Vice President – Operations & IT



Sunil Wason Vice President - Procurement



Dr. L C Rohela Senior General Manager - QA




Dr. Mukesh Kumar General Manager – R&D



Sanjay Singh GM – Market Development



Exports - How We Have Grown?













R&D'S ENDEAVOURS TO LAUNCH NEW **PRODUCTS IN** THE MAHARATNA **CATEGORY:**

Launched 7 new products in FY21 Focus on in-house R&D and international partners to launch new products Will launch 5 new generation products in the current fiscal

INCREASING EXPORT PENETRATION:

Working on registration in new countries with 100+ **Export agreements**

STRENGTHENING BALANCE SHEET AND IMPROVING **OPERATIONAL EFFICIENCY:**

Focus on sustainable

generation of cash flows. **Consistent reduction in Debt** Spending on Capex of ₹1.1 bn (for FY21 and FY22 combined) in a phased manner for increasing capacities, setting up technical synthesis plant at SEZ and backward integration plants at Gujarat and Rajasthan.

Out of ₹ 1.1 bn, half of the amount has already been deployed.

BACKWARD AND FORWARD INTEGRATION:

Moving on the strategic path of backward and forward integration Capitalize on the "Make in India" initiative

These endeavours will help in elevating the margin profile.

EXPANDING ITS GLOBAL FOOTPRINTS:

Working towards increasing Exports to 50+ countries, serving 100+ clients by end of FY23 from current Exports to 20+ countries.


FOCUSSED APPROACH ON BIOLOGICALS:

Developed and commercialized VAM (Vesicular Arbuscular Mycorrhiaze) **Developed and** commercialized soil energizer, KK PRO Developed 3 new

TAIL-CUTTING POLICY:

Strategy to phase out **Generic Products (high** volume-low margin products).

Continuous efforts and expenditure on R&D to launch new products in Maharatna Category in order to move up the value chain.





IIL's Robust Strategy on: Exports, China and Covid

EXPORTS



KEY CHALLENGES

- Marginal growth in Exports in the last 2 years saturated at ~ 650-675 million.
- Unstable geopolitical situation and trade sanctions.
- Shipment and logistic issue due to non-availability of containers.
- Slowdown in registration and regulatory process in overseas countries due to pandemic issues.
- Supply chain disruption.



IIL'S STRATEGY

- Q Geographical expansion and Market diversification.
- Transition from CIF to FOB based model logistics cost in order to keep cost under control.
- Focus on backward integration to avoid supply chain disruption.
- Regulatory data support for all our in-house manufactured products for sustainable business.

RAW MATERIAL PROCUREMENT FROM CHINA



KEY CHALLENGES

Some raw materials required for manufacturing of its formulations were procured from international market specially from China.



IIL'S STRATEGY

Company, in its endeavours to reduce its dependency on China, has invested in Capex to manufacture the technicals required for the production of its formulations.

This will also help the company to be backward integrated, enabling it to enhance its margin profile.

IMPACT OF COVID-19 ON BUSINESS:



KEY CHALLENGES

Due to outbreak of the pandemic, IIL had been witnessing the following issues:

- Increase in credit terms required by its dealer/distributor network.
- Difficulty in pushing its products to the customers due to lockdowns and restriction in movements of its Sales Force.



IIL'S STRATEGY

- Categorization of dealers/distributors with allowing enhanced credit for prime dealers and reduced credit for sub-prime dealers.
- O Company has also migrated to cash-andcarry model and both these endeavours has helped company largely in reducing its working capital cycle and receivable days.
- IIL has taken Digital Initiatives to resolve the issue of reaching out to its customers. It has been successful in maintaining the required level of engagements with its customers through whatsapp and social media and it has also helped the company in creating awareness for its new products amongst the farmer community.







SHORT TERM

LAUNCH NEW GENERICS AND PRODUCTS GOING OFF-PATENT

MEDIUM TERM

TO LAUNCH LATEST TECHNOLOGY PRODUCTS
THROUGH INTERNATIONAL PARTNERS;
LAUNCH NEW COMBINATIONS AND FORMULATIONS

LONG TERM

LAUNCH PROPRIETARY DISCOVERY PRODUCTS





IIL's Forward-Looking Strategy and Guidance

FORWARD-LOOKING STRATEGY

- From a generic agro chemicals player, the company has developed a threepronged growth strategy, which focuses on R&D, Manufacturing and Marketing.
- Company will be increasing its global footprints and intends to Export to 50+ countries from current 20+ countries in 2 years. It is also working towards having more no. of products registered in foreign countries.
- Negotiating with partners for launching new products in the Indian market
- Management sees a huge opportunity in the Exports segment.
- Enhancing capacities to cater to the existing and upcoming demand



GUIDANCE

- The management expects the top line to grow by ~10-15% for FY22, mainly driven by expansion of facilities, addition of new generation products, and a high number of product registrations expected in the current fiscal. The new generation products will not only help in top line and bottomline growth, but also help in margin accretion.
- The management expects the EBITDA margins to improve by 100 BPS from 10.7% in FY21 to 11.7% in FY22 and PAT margins to improve by 100 BPS from 6.5% in FY21 to 7.5% in FY22, attributed to better product mix, cost optimization measures and backward integration for certain raw materials.
- The management has a target of achieving more than ₹ 1,000 mn of revenue through Exports. This will be achieved by penetrating newer geographies and getting a greater number of products registered in different countries.
- The management expects to launch 5 new generation products, by end of FY22.



Global Partners

Collaborations with International Players for Manufacturing and Marketing of Innovative Products:

MOMENTIVE

USA

Tie-up with MOMENTIVE Performance Material Inc., USA for AGROSPRED* MAX for silicone based super spæader



NISSAN CHEMICAL CORPORATION JAPAN

Marketing Tie-up for specialty products i.e. PULSOR, Fungicide, HAKAMA, Selective Herbicide & KUNOICHI, Miticide





Marketing tie-up for SUZUKA, HAKKO & AIKIDO



OAT Agrio Co., Ltd. JAPAN

Tie-up with OAT Agrio Co., Ltd.
Japan to bring a specialised product for Seed treatment,
ROOTBEAD & TADAAKI, a broad spectrum insecticide








JV for a dedicated R&D Centre in India to invent new agrochemical molecules











Segmental Reporting - Q1FY22


















Key Performance Highlights





* Figures in ₹in Million






















WC Cycle

Declining trend of Working Capital Cycle










- Q Net Working Capital Cycle has been declining over the years and funding of working capital is through internal accruals.
- O Decline in Receivable Days in FY21 is attributed to the transition to the Cash-and-Carry Model that the company has been implementing in these pandemic times.



Cash Flow from Operations v/s Free Cash Flow

Generation of positive Free Cash Flows for Capex and Repayment of Debt





(₹in Mn)



Leverage Profile

Strengthening Company's B/S and Cash Position

Particulars (₹ in Mn)	FY19	FY20	FY21
LT Debt	68	19	23*
ST Debt	2,952	1,835	916
Total Debt	3,020	1,854	939
C&CE	92	742	833
Net Debt	2,928	1112	106
Total Equity	6,613	7,302	8,184
Net D/E	0.44	0.15	0.01

- Company continues to strengthen Balance Sheet by reducing debt and improving collection process
- Company is improving its Cash Position by implementing Cash-and-Carry Model

Notes:

- 1. Long Term Debt also includes Current Maturities of Long-Term Debt *Term Loan is zero from end of FY20
- 2. Total Debt includes Vehicles Loans
- 3. Capital Employed = Total Debt + Total Equity





Financial Performance

Quarterly Performance Q1FY22 v/s Q1FY21:

Particulars (INR MN)	Q1FY22	Q1FY21
Revenue from Operations	4682.61	4095.99
Other Income	16.30	11.24
Total Revenue	4698.91	4107.23
Total Expenses	4236.74	3687.38
EBITDA	530.82	492.08
EBITDA Margin (%)	11.30%	11.98%
Depreciation	63.40	61.01
Finance Cost	21.54	22.46
PBT with Exceptional Item	464.64	422.68
Exceptional Items		100.00
PBT	464.64	322.68
Current Tax	115.88	81.55
Earlier Years		
Deferred Tax	-0.84	-2.51
Tax	115.04	79.04
PAT	349.60	243.64
Other comprehensive profit / loss	-4.48	-0.18
Net PAT	345.12	243.46
PAT Margin %	7.34%	5.93%
Diluted EPS	17.37	11.79

Quarterly Highlights:

- Strong growth in Sales in Q1 FY2022 on both sequential and on y-o-y basis.
 - Revenue from Operations increased by 14.3% on y-o-y basis driven by increase in Institutional Sales (+28.7% y-o-y) and Exports (+179.4% y-o-y)
 - Branded sales increased by 2.1% y-o-y, led by Maharatna products which grew by 6.4% y-o-y, contributing 41.5% to total Branded Sales. Lethal group of products are receiving positive response in the market as a substitute of Nuvan and Thimet
- Operating margins marginally impacted due to higher contribution of Institutional Sales, however Net Profit margins improved significantly towards pre-Covid level





Financial Performance:

Consolidated P&L

Particulars (INR MN)	FY19	FY20	FY21
Revenue from Operations	11935.09	13632.20	14202.26
Other Income	7.44	25.66	77.28
Total Revenue	11942.53	13657.85	14279.54
Total Expenses	10412.47	12553.24	12992.18
EBITDA	1871.66	1558.57	1523.31
EBITDA Margin (%)	15.67%	11.41%	10.67%
Depreciation	196.81	240.72	246.72
Finance Cost	152.22	238.90	66.51
PBT with Exceptional Item	1530.06	1104.61	1287.36
Exceptional Items			97.02
PBT	1534.14	1113.34	1195.04
Current Tax	284.31	253.89	305.11
Earlier Years	21.69		
Deferred Tax		-9.69	-49.10
Tax	306.00	244.21	256.01
PAT	1228.14	869.13	939.03
Other comprehensive profit / loss	-36.68	-22.39	-11.23
Net PAT	1191.46	846.75	927.80
PAT Margin %	9.98%	6.20%	6.50%
Diluted EPS	59.42	42.05	45.43





Financial Performance

Consolidated Balance Sheet:

Particulars (INR MN)	FY19	FY20	FY21
Non-Current Assets			
Property, plant and equipment	2371.50	2089.31	2085.35
Capital work-in-progress	127.14	328.84	518.72
Right of Use Assets		251.47	258.46
Intangible Assets	30.50	50.19	44.18
Intangible Assets under Development	62.87	60.75	67.75
Investment in JV and Associates	86.06	94.45	99.28
Financial Assets			
Investments	38.80	24.50	36.20
Other financial assets	15.68	16.08	28.05
Non-current tax assets (net)	45.49	139.69	107.21
Other non-current assets	153.13	105.61	153.43
Total non-current assets	2931.18	3160.89	3398.63
Current assets			
Inventories	7051.07	5192.65	6608.73
Financial Assets			
Trade receivables	2442.49	3197.87	2545.87
Cash and cash equivalents	89.42	677.31	64.74
Bank balances other above	2.98	64.30	768.29
Loans	121.66	27.28	0.51
Other financial assets	45.86	60.42	43.50
Other current assets	870.81	563.48	829.31
Total current assets	10624.28	9783.32	10860.94
Total assets	13555.47	12944.21	14259.57





Financial Performance

Consolidated Balance Sheet (Continues)

Particulars (INR MN)	FY19	FY20	FY21
Equity			
Equity Share capital	206.68	206.68	206.68
Other Equity	6413.36	7110.61	7997.07
Total Equity	6620.04	7317.29	8203.75
Non-current Liabilities			
Financial Liabilities			
Borrowings	13.16	19.05	23.95
Lease liabilities		17.63	25.34
Provisions	7.49	10.39	27.68
Deferred tax liabilities (net)	178.69	186.78	133.57
Total non-current liabilities	199.34	233.85	210.54
Current liabilities			
Financial Liabilities			
Borrowings	2951.72	1834.82	916.09
Lease liabilities		19.27	16.34
Trade Payables	2798.66	2465.58	3620.33
Other financial liabilities	301.42	291.12	262.76
Other current liabilities	670.86	756.48	1002.15
Provisions	13.42	25.81	27.49
Total current liabilities	6736.09	5393.07	5845.16
Total equity and liabilities	13555.47	12944.21	14259.44





Capital Market Information

MARKET INDICATORS:

CMP

(as on 25th Aug, 2021):

₹ 705.55

BSE Scrip Code:

532851

NSE Symbol:

INSECTICID

52 Week H/L:

846/399


2W Avg Vol:

3298

Market Cap


(as on 25th Aug, 2021)

in Mn: ₹ 13,975.3



Shareholding Pattern

Particulars	No. of Shareholders	No. of Shares held	Percentage Shareholding
Promoters & Promoters group	9	1,42,38,270	72.16
Institutions	16	28,81,142	14.60
Public	15,858	26,12,479	13.24
Total	15,883	1,97,31,891	100.00





CSR

Over the last couple of years, it has been working on the following projects:

- Spreading awareness about the judicious use of agrochemicals in rural as well as urban societies.
- Collaborating with rural schools to help children get better access to quality education.
- IIL Foundation and National Food Security Mission (NFSM) have been working with farmers in the backward areas of Andhra Pradesh and Telangana to educate them about the latest techniques of farming and crop protection products.
- On the occasion of World Environment Day, IIL Foundation planted Trees for a better tomorrow. The plantation drive was conducted, near our plant at Chopanki, Rajasthan. Around 100 trees were planted in and around schools in Jodiamev and Chopanki.
- Distribution of masks and Sanitizers to farmers and Schools, donating oxygen concentrators and supporting the local administrative bodies in local awareness programs were on of the few initiatives under the Covid Prevention activities.









Thank You

For further information on the Company, please visit www.insecticidesindia.com

SANDEEP AGARWAL, CFO

Insecticides (India) Limited

Contact: +91 11 2767 9700

Email: sandeep@insecticidesindia.com

KRUNAL SHAH/ VINAYAK SHIRODKAR

Captive IR Strategic Advisors Pvt. Ltd
Contact: +91 98922 88895

Email: krunal@cap-ir.com/vinayak@cap-ir.com